The serotonin paradox: Negative symptoms and SSRI augmentation

References

• World Health Organisation. World Health Report 1995. WHO, Geneva 1995
   Google Scholar
• Kane JM. Factors which can make patients difficult to treat. Br J Psychiatry 1996; 169: 10–14, Suppl. 31
   PubMed Web of Science ®Google Scholar
• Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988; 45: 789–96
   PubMed Web of Science ®Google Scholar
• Krupp P, Barnes P. Leponex-associated granulocytopenia: a review of the situation. Psychopharmacology 1989; 99: 118–21
   PubMed Web of Science ®Google Scholar
• Amsler H A., Teerenhovi L, Barth E, et al. Agranulocytosis in patients treated with clozapine–A study of the Finnish epidemic. Acta Psychiatr Scand 1977; 56: 241–8
   PubMed Web of Science ®Google Scholar
• Gaebel W, Wölwer W. Probleme der Abgrenzung von Depression, Akinesie und Minussymptomatik mittels Beurteilungsskalen und Verhaltensbeobachtung: Messmethodisches Artefakt oder Ausdruck pathogenetischer Identität?. Fortschritte in der Diagnostik und Therapie schizophrener Minussymptomatik, HJ. Möller, G. Laux. Springer-Verlag, Wien 1994; 27–38
   Google Scholar
• Newcomer J W., Faustman W O., Yeh W, et al. Distinguishing depression and negative symptoms in unmedicated patients with schizophrenia. Psychol Rep 1990; 31: 243–50
   Google Scholar
• Plasky P. Antidepressant usage in schizophrenia. Schizophr Bull 1991; 17: 649–57
   PubMed Web of Science ®Google Scholar
• Siris SG. Adjunctive medication in the maintenance treatment of schizophrenia and its conceptual implications. Br J Psychiatry 1993; 163: 66–78
   Web of Science ®Google Scholar
• Evans A E., Goff DC. Adjunctive antidepressant drug therapies in the treatment of negative symptoms of schizophrenia. CNS Drugs 1996; 6: 130–47
   Web of Science ®Google Scholar
• Siris S, Bermanzohn P C., Gonzales A, et al. The use of antidepressants for negative symptoms in a subset of schizophrenic patients. Psychopharmacol Bull 1991; 27: 331–5
   PubMedGoogle Scholar
• Boyer W F., Feighner JP. Safety and tolerability of selective serotonin re-uptake inhibitors. Selective serotonin re-uptake inhibitors, JP. Feighner, WF. Boyer. J Wiley, Chichester 1996
   Google Scholar
• Iqbal N, van Praag M. The role of serotonin in schizophrenia. Eur Neuropsychopharmacol 1995; 11–23, Suppl. 5
   PubMed Web of Science ®Google Scholar
• Meltzer HY. The importance of serotonin-dopamine interactions in the action of clozapine. Br J Psychiatry 1992; 160: 22–9
   Web of Science ®Google Scholar
• Richelson E. Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry 1996; 57: 4–11
   PubMed Web of Science ®Google Scholar
• Marder S R., Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825–35
   PubMed Web of Science ®Google Scholar
• Carman J, Peuskens J, Vangeneugen A. Risperidone in the treatment of negative symptoms of schizophrenia: a metaanalysis. Int Clin Psychopharmacol 1995; 10: 207–13
   PubMed Web of Science ®Google Scholar
• Rossi A, Mancini F, Stratta P, et al. Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. Acta Psychiatr Scand 1997; 95: 40–3
   PubMed Web of Science ®Google Scholar
• Azorin JM. Long-term treatment of mood disorders in schizophrenia. Acta Psychiatr Scand 1995; 91: 20–3
   Web of Science ®Google Scholar
• Fleischhacker WW. New drugs for the treatment of schizophrenic patients. Acta Psychiatr Scand 1995; 91: 24–30
   Web of Science ®Google Scholar
• Smith R C., Chua J W., Lipetsker B, et al. Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: An open prospective study. J Clin Psychiatry 1996; 57: 460–66
   PubMed Web of Science ®Google Scholar
• Borison RL. Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. J Clin Psychopharmacol 1995; 15: 24S–29S
   PubMed Web of Science ®Google Scholar
• Hillert A, Maier W, Wetzel H, et al. Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome–A functional approach. Pharmacopsychiatry 1992; 25: 213–7
   PubMed Web of Science ®Google Scholar
• Hamon M. Sérotonine/5-hydroxytryptamine (5-HT). Neuropeptides et neuromédiateurs, J. Epelbaum, InsermParis 1995; 261–70
   Google Scholar
• Silver H, Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: An add-on double-blind, placebo-controlled study. Biol Psychiatry 1992; 31: 698–704
   PubMed Web of Science ®Google Scholar
• Spina E, De Domenico P, Ruello C, et al. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int Clin Psychopharmacol 1994; 9: 281–5
   PubMed Web of Science ®Google Scholar
• Goff D C., Midha K K., Sarid-Segal O, et al. A placebocontrolled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology 1995; 117: 417–23
   PubMed Web of Science ®Google Scholar
• Vartiainen H, Tiihonen J, Putkonen A, et al. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiatr Scand 1995; 91: 348–51
   PubMed Web of Science ®Google Scholar
• Salokangas R KR, Saarijäm S, Taiminen T, et al. Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. Acta Psychiatr Scand 1996; 94: 175–80
   PubMed Web of Science ®Google Scholar
• Taiminen T, Syvälathi E, Saarijärvi S, et al. Citalopram as an adjuvant in schizophrenia: further evidence for a serotonergic dimension in schizophrenia. Int Clin Psychopharmacol 1997; 12: 31–5
   PubMed Web of Science ®Google Scholar
• Goff D C., Brotman A W., Waites M, et al. Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients. Am J Psychiatry 1990; 147: 492–4
   PubMed Web of Science ®Google Scholar
• Syvälathi E KG, Kallioniemi H, Lehto H. Citalopram in patients with unsatisfactory response to neuroleptics: An open follow-up study. Meth Find Exp Clin Pharmacol 1994; 16: 49–55
   PubMedGoogle Scholar
• Silver H, Kaplan A, Kushnir M. Fluvoxamine augmentation in chronic schizophrenia: An open exploratory study. Hum Psychopharmacol 1995; 10: 59–63
   Web of Science ®Google Scholar
• Bacher N M., Ruskin P. Addition of fluoxetine to treatment of schizophrenic patients. Am J Psychiatry 1991; 148: 274–5
   PubMed Web of Science ®Google Scholar
• Thakore J H., Berti C, Dinan TG. An open trial of adjunctive sertraline in the treatment of chronic schizophrenia. Acta Psychiatr Scand 1996; 94: 194–7
   PubMed Web of Science ®Google Scholar
• Baldessarini R J., Frankenburg FR. Clozapine. A novel antipsychotic agent. N Engl J Med 1991; 324: 746–54
   PubMed Web of Science ®Google Scholar
• Barnes T RE, McEvedy C JB, Nelson HE. Management of treatment resistant schizophrenia unresponsive to clozapine. Br J Psychiatry 1996; 169: 31–40
   Web of Science ®Google Scholar
• Buchanan R W., Kirkpatrick B, Bryant N, et al. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am J Psychiatry 1996; 153: 1625–7
   PubMed Web of Science ®Google Scholar
• Silver H, Kaplan A, Jahjah N. Fluvoxamine augmentation for clozapine-resistant schizophrenia. Am J Psychiatry 1995; 152: 1098
   PubMed Web of Science ®Google Scholar
• Silver H, Kushnir M, Kaplan A. Fluvoxamine augmentation in clozapine-resistant schizophrenia: An open pilot study. Biol Psychiatry 1996; 40: 671–4
   PubMed Web of Science ®Google Scholar
• Arndt S, Andreasen N C., Flaum M, et al. A longitudinal study of symptoms dimensions in schizophrenia. Arch Gen Psychiatry 1995; 52: 352–60
   PubMed Web of Science ®Google Scholar
• Salokagas R KR. Structure of schizophrenic symptomatology and its changes over time: Prospective factor- analytical study. Acta Psychiatr Scand 1997; 95: 32–9
   PubMed Web of Science ®Google Scholar
• Carpenter WT. Serotonin-dopamine antagonists and treatment of negative symptoms. J Clin Psychopharmacol 1995; 15: 30S–35S
   PubMed Web of Science ®Google Scholar
• Czobon P, Volavka J. Positive and negative symptoms: Is their change related?. Schizophr Bull 1996; 22: 577–90
   PubMed Web of Science ®Google Scholar
• Tollefson G D., Sanger TM. Negative symptoms: A path analytic approach to a double-blind, placebo- and haloperidol- controlled clinical trial with olanzapine. Am J Psychiatry 1997; 154: 466–74
   PubMed Web of Science ®Google Scholar
• Lipinski J F., Mallya G, Zimmermann P, et al. Fluoxetine- induced akathisia: Clinical and theoretical implications. J Clin Psychiatry 1989; 50: 339–42
   PubMed Web of Science ®Google Scholar
• Bouchard R H., Pourcher E, Vincent P. Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1989; 146: 1352–3
   Web of Science ®Google Scholar
• Halman M, Goldbloom DS. Fluoxetine and neuroleptic malignant syndrome. Biol Psychiatry 1990; 28: 518–21
   PubMed Web of Science ®Google Scholar
• Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996; 57: 449–54
   PubMed Web of Science ®Google Scholar
• Hamilton M S., Opler LA. Akathisia, suicidality, and fluoxetine. J Clin Psychiatry 1992; 53: 401–6
   PubMed Web of Science ®Google Scholar
• Sanz-Fuentenebro F J., Huidobro A, Tejadas-Rivas A. Restless legs syndrome and paroxetine. Acta Psychiatr Scand 1996; 94: 482–4
   PubMed Web of Science ®Google Scholar
• Balant-Gorgia A E., Ries C, Balant LP. Metabolic interaction between fluoxetine and clomipramine: A case report. Pharmacopsychiatry 1996; 29: 38–41
   PubMed Web of Science ®Google Scholar
• Tate JL. Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine. Am J Psychiatry 1989; 146: 399–400
   PubMed Web of Science ®Google Scholar
• Stein MH. Tardive dyskinesia in a patient taking haloperidol and fluoxetine. Am J Psychiatry 1991; 148: 683
   PubMed Web of Science ®Google Scholar
• Preskom SH. Clinical pharmacology of selective serotonin reuptake inhibitors. Professional Communications Inc, Caddo, OHUSA 1996
   Google Scholar
• Dubovsky S L., Thomas M. Serotonergic mechanisms and current and future psychiatric practice. J Clin Psychiatry 1995; 56: 38–48
   PubMed Web of Science ®Google Scholar
• Meltzer H Y., Okaly G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: Impact on risk-benefit assessment. Am J Psychiatry 1995; 152: 183–90
   PubMed Web of Science ®Google Scholar
• Tamminga C A., Holcomb H H., Gao WM, et al. Glutamate pharmacology and the treatment of schizophrenia: current status and future directions. Int Clin Psychopharmacol 1995; 10: 29–37
   PubMed Web of Science ®Google Scholar
• Müller-Spahn F, Eich P, Hock C. The psychobiology of the acute schizophrenic episode. Int Clin Psychopharmacol 1996; 11: 19–28
   PubMed Web of Science ®Google Scholar
• Jerling M, Dahl M L., Aberg-Wistedt A. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clin Pharmacol Ther 1996; 59: 423–8
   PubMed Web of Science ®Google Scholar
• Linnet K, Wiborg O. Influence of CYP2D6 polymorphism on ratios of steady-state serum concentration to dose of the neuroleptic zuclopenthixol. Ther Drug Monit 1996; 18: 629–34
   PubMed Web of Science ®Google Scholar
• Haring C, Meise U, Humpel C, et al. Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacol 1989; 99: S38–S40
   Web of Science ®Google Scholar
• Hiemke C, Weigman H, Hätter S, et al. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 1994; 14: 279–81
   PubMed Web of Science ®Google Scholar
• Brunette M F., Muesner K T., Haiyi X, et al. Relationships between symptoms of schizophrenia and substance abuse. J Nerv Ment Dis 1997; 185: 13–20
   PubMed Web of Science ®Google Scholar
• Llerena A, Kilvet RA. Fixed combinations of neuroleptics with antidepressants: potential risks and estimation of use. Br J Clin Pharmacol 1994; 37: 531–2
   PubMed Web of Science ®Google Scholar